ATE233318T1 - Spezifische oligonukleotide für hepatitis b virus - Google Patents

Spezifische oligonukleotide für hepatitis b virus

Info

Publication number
ATE233318T1
ATE233318T1 AT96918671T AT96918671T ATE233318T1 AT E233318 T1 ATE233318 T1 AT E233318T1 AT 96918671 T AT96918671 T AT 96918671T AT 96918671 T AT96918671 T AT 96918671T AT E233318 T1 ATE233318 T1 AT E233318T1
Authority
AT
Austria
Prior art keywords
hepatitis
virus
specific oligonucleotides
hbv
kits
Prior art date
Application number
AT96918671T
Other languages
English (en)
Inventor
Charles J Craig
Bruce L Frank
John Goodchild
Raymond Jupp
Robert E Kilkuskie
John S Mills
Noel A Roberts
Peter C Roberts
Andrew Slade
Original Assignee
Hybridon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybridon Inc filed Critical Hybridon Inc
Application granted granted Critical
Publication of ATE233318T1 publication Critical patent/ATE233318T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/313—Phosphorodithioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT96918671T 1995-06-06 1996-06-04 Spezifische oligonukleotide für hepatitis b virus ATE233318T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46739795A 1995-06-06 1995-06-06
PCT/EP1996/002432 WO1996039502A1 (en) 1995-06-06 1996-06-04 Oligonucleotides specific for hepatitis b virus

Publications (1)

Publication Number Publication Date
ATE233318T1 true ATE233318T1 (de) 2003-03-15

Family

ID=23855522

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96918671T ATE233318T1 (de) 1995-06-06 1996-06-04 Spezifische oligonukleotide für hepatitis b virus

Country Status (10)

Country Link
US (2) US5856459A (de)
EP (1) EP0832211B1 (de)
AT (1) ATE233318T1 (de)
AU (1) AU6125296A (de)
CA (1) CA2226458A1 (de)
DE (1) DE69626393T2 (de)
DK (1) DK0832211T3 (de)
ES (1) ES2188760T3 (de)
WO (1) WO1996039502A1 (de)
ZA (1) ZA964445B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040054156A1 (en) * 1992-05-14 2004-03-18 Kenneth Draper Method and reagent for inhibiting hepatitis B viral replication
US5646262A (en) 1994-07-28 1997-07-08 Georgetown University Antisense oligonucleotides against hepatitis B viral replication
US5985662A (en) * 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
EP0952982B1 (de) 1996-10-31 2003-12-03 Biogen, Inc. Hepatitis b inhibitoren
CN1057302C (zh) * 1997-08-27 2000-10-11 中国科学院上海生物化学研究所 抑制乙型肝炎病毒复制的反义脱氧寡核苷酸
CN1215058A (zh) * 1997-10-21 1999-04-28 中国科学院上海生物化学研究所 新的三链形成寡核苷酸结构及其在抗乙肝病毒中的应用
TR200102423T2 (tr) 1998-12-04 2002-02-21 Biogen, Inc. Peptid ligandları yoluyla bağlı birden fazla imünojenik bileşeni olan HBV çekirdek antijeni parçacıkları
AU2001254670A1 (en) * 2000-03-02 2001-09-12 Akzo Nobel N.V. Detection of hepatitis b virus rna
US6583279B1 (en) 2001-01-26 2003-06-24 Becton, Dickinson And Company Sequences and methods for detection of hepatitis B virus
EP1383782A1 (de) * 2001-03-26 2004-01-28 Sirna Therpeutics, Inc. Oligonukleotidvermittelte inhibierung der replikation des hepatitis--b-virus und des hepatitis-c-virus
WO2002092006A2 (en) 2001-05-16 2002-11-21 Micrologix Biotech, Inc. Nucleic acid-based compounds and methods of use thereof
US20030140362A1 (en) * 2001-06-08 2003-07-24 Dennis Macejak In vivo models for screening inhibitors of hepatitis B virus
ATE519861T1 (de) 2002-06-14 2011-08-15 Gen Probe Inc Zusammensetzungen zum nachweis von hepatitis-b- virus
EP1403385A1 (de) * 2002-09-27 2004-03-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methode zur Darstellung der Replikation von HBV und zum Testen der Sensibilität von Wirkstoffen
CN1753687A (zh) * 2002-10-29 2006-03-29 科勒制药集团股份有限公司 Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
BR112012008865A2 (pt) 2009-10-16 2019-09-24 Glaxo Group Ltd inibidores de hbv anti-sentido.
RS61447B1 (sr) * 2011-04-21 2021-03-31 Glaxo Group Ltd Modulacija ekspresije virusa hepatitisa b (hbv)
EA024762B9 (ru) 2011-06-30 2017-04-28 Эрроухэд Рисерч Корпорейшн Композиции и способы ингибирования экспрессии генов вируса гепатита в
GB201408623D0 (en) 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
AU2016306275A1 (en) 2015-08-07 2018-02-08 Arrowhead Pharmaceuticals, Inc. RNAi therapy for Hepatitis B virus infection
JOP20190015A1 (ar) 2016-08-04 2019-02-04 Arrowhead Pharmaceuticals Inc عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
KR102273071B1 (ko) * 2018-06-12 2021-07-05 주식회사 에이엠사이언스 B형 간염 예방 또는 치료용 조성물
WO2019240504A1 (en) * 2018-06-12 2019-12-19 Am Sciences Co., Ltd. Modified oligonucleotides for inhibition of target gene expression

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225326A (en) * 1988-08-31 1993-07-06 Research Development Foundation One step in situ hybridization assay
US5610050A (en) * 1990-04-20 1997-03-11 The General Hospital Corporation Methods of preventing viral replication
WO1992006693A1 (en) * 1990-10-22 1992-04-30 Fox Chase Cancer Center Dna construct for providing rna therapy
EP0666923A1 (de) * 1991-09-05 1995-08-16 The University Of Connecticut Gezielte bereitstellung von poly- oder oligonukleotiden in zellen
US5585479A (en) * 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
WO1995017414A1 (en) * 1993-12-23 1995-06-29 Apollon, Inc. Anti-hepatitis b viral oligonucleotides
US5728518A (en) * 1994-01-12 1998-03-17 The Immune Response Corporation Antiviral poly-and oligonucleotides
US5646262A (en) * 1994-07-28 1997-07-08 Georgetown University Antisense oligonucleotides against hepatitis B viral replication

Also Published As

Publication number Publication date
WO1996039502A1 (en) 1996-12-12
DE69626393T2 (de) 2003-12-04
US5856459A (en) 1999-01-05
ES2188760T3 (es) 2003-07-01
DK0832211T3 (da) 2003-05-26
CA2226458A1 (en) 1996-12-12
EP0832211B1 (de) 2003-02-26
DE69626393D1 (de) 2003-04-03
EP0832211A1 (de) 1998-04-01
US6984729B1 (en) 2006-01-10
ZA964445B (en) 1996-12-06
AU6125296A (en) 1996-12-24

Similar Documents

Publication Publication Date Title
DE69626393D1 (de) Spezifische oligonukleotide für hepatitis b virus
DE69403642D1 (de) 7-deazapurin modifizierte oligonukleotide
DE69829115D1 (de) Zusammensetzungen und verfahren zur behandlung von hepatitis c virus-bedingten erkrankungen
DE69330372D1 (de) ZUSAMMENSETZUNGEN UND VERFAHREN FüR DIE BEHANDLUNG VON MIT HEPATITIS C VIREN ASSOZIIERTEN KRANKHEITEN
ATE421883T1 (de) Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
NO20030845D0 (no) Utvalgte fusjonerte pyrrolokarbazoler
NO983716D0 (no) Metoksyetoksy oligonukleotider for modulering av protein-kinase C ekspresjon
DE60137631D1 (de) Ireovirus antikörpern zur behandlung von ras-vermittelten, proliferativen erkrankungen
DK1123414T3 (da) Antisense-modulering af integrin alpha 4.ekspression
PT1023310E (pt) Sintese melhorada de oligonucleotidos sulfurados
EP1131107A4 (de) Antisense-modulation der expression von inhibitor-kappa-b-kinase-alpha
DE60015568D1 (de) Zusammensetzungen zur behandlung von viralen infektionen und verfahren dafür
ES2091928T3 (es) Metodos de prevencion de la replicacion virica.
ATE369429T1 (de) Strukturproteine des virus, welches die pankreas- krankheit bei fischen verursacht, und ihre verwendungen
WO1996039500A3 (en) Oligonucleotides specific for hepatitis c virus
DE69739346D1 (de) Gereinigtes sr-p70 protein
AU2180501A (en) Novel DNA polymerase inhibitors, mikanolide and dihydromikanolide
WO1996039501A3 (en) Oligonucleotides specific for human papillomavirus
DE69922364D1 (de) Verfahren zur immunisierung und behandlung von h. pylori infektion
EA199700438A1 (ru) Межгенные участки вируса верхушки банановой грозди
ATE493408T1 (de) Antiinfektiöse mittel
EP0975216A4 (de) Verfahren zur behandlung von papillomavirus-infektionen
HU9300349D0 (en) Method for producing dibenzo- or benzo-pyrido-cyclohepta-piperidine derivatives or piperidylidene or piperazine derivatives thereof as well as pharmaceutical preparatives contqining them
ATE212839T1 (de) Hämoregulatorische verbindungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties